ABSTRACT: Vascular Endothelial Growth Factor (VEGF) protects the brain against ischemic injury in adult animals. We evaluated whether VEGF has neuroprotective effects against hypoxic-ischemic (HI) brain injury in newborn rats. Seven-day-old rat pups had the right carotid artery permanently ligated followed by 140 min of hypoxia (8% oxygen). VEGF (5, 10, 20, or 40 ng) or vehicle was administered intracerebroventricularly 5 min after reoxygenation following HI. Brain damage was evaluated by weight loss of the right hemisphere at 22 d after HI and by gross and microscopic morphology. Body weight, rectal temperature, and mortality were not significantly different in the VEGF and vehicle treated groups. VEGF treatment increased brain VEGF levels at 15 min after injection. VEGF (10 and 20 ng) significantly reduced brain weight loss (p Ͻ 0.05) and gross brain injury (p Ͻ 0.05); however, treatment with 5 or 40 ng did not. VEGF (10 ng) also decreased brain damage assessed by histologic scoring. VEGF increased phosphorylation of protein kinase B (Akt) and extracellular-signal regulated kinase 1/2 (ERK1/2) in the cortex (p Ͻ 0.05). These results suggest that VEGF has neuroprotective effects in the neonatal rat HI model that may be related to activation of the Akt/ERK signaling pathway. N eonatal hypoxic-ischemic (HI) cerebral injury, the most common known cause of cerebral palsy, is an evolving process that is initiated during the insult and extends into a recovery period, the "reperfusion phase," which is amenable to potential intervention(s) (1,2). Novel strategies aimed at preventing ongoing injury are being clinically evaluated and offer an opportunity for neuroprotection (3). The neonatal rat model of HI has been well characterized (4) and used extensively to assess the efficacy of neuroprotective agents (5).
N eonatal hypoxic-ischemic (HI) cerebral injury, the most common known cause of cerebral palsy, is an evolving process that is initiated during the insult and extends into a recovery period, the "reperfusion phase," which is amenable to potential intervention(s) (1, 2) . Novel strategies aimed at preventing ongoing injury are being clinically evaluated and offer an opportunity for neuroprotection (3) . The neonatal rat model of HI has been well characterized (4) and used extensively to assess the efficacy of neuroprotective agents (5) .
Vascular Endothelial Growth Factor A (VEGF), an angiogenic growth factor and survival factor for endothelial cells, also exhibits neurotrophic and neuroprotective effects. Exogenously applied VEGF enhances survival of mesencephalic neurons in organotypic explant cultures (6) . VEGF also reduces hypoxic death of both immortalized hippocampal neuronal cells and cultured cerebral cortical neurons (7, 8) . Recent data suggest that VEGF protects the brain against ischemic injury in adult animals (9 -11) , but limited information is available in newborn animals.
Evidence suggests that apoptosis contributes significantly to injury in the delayed phase after milder degrees of neonatal HI (12) . The serine-threonine kinase, protein kinase B (Akt) is one of the major downstream pathways of neurotrophin signaling and plays a critical role in controlling the balance between survival and apoptosis (13) . Activation of Akt has been shown to promote neuronal survival after ischemia (14, 15) . Extracellular Signal-Regulated Kinases (ERK 1/2 or ERKs) are known to be involved in cell proliferation, differentiation, and survival. Functional relevance of ERKs activation depends upon the type of cell and the nature of the stimulus (16) . Evidence suggests they have a role in the induction of tolerance to ischemic injury in heart, adult brain, and neonatal brain (16) . Previous studies have suggested that the molecular mechanisms of neuroprotective effects of VEGF involve activation of Akt and/ or ERKs (7, 17, 18) .
In the present study, we investigated whether VEGF treatment would reduce brain injury in the neonatal rat HI model and the potential mechanisms of neuroprotection.
MATERIALS AND METHODS
Animal protocol. The protocol was approved by the University of Mississippi institutional committee on animal use. Rats were cared for in accordance with National Institutes of Health guidelines. The neonatal rat HI procedure was performed as described by Rice et al. (4) with minor modifications. Seven-day-old Sprague-Dawley rat pups of either sex, weighing between 12 and 16 g (Charles River Laboratories, Wilmington, MA) were anesthetized with 3% isoflurane. The right common carotid artery was exposed, isolated and permanently doubly ligated. After surgery, the rat pups were returned to their dams for 2-3 h recovery. Hypoxic exposure was achieved by placing the rat pups in 1.5-l sealed jars immersed 5.5-cm deep in a 37°C water bath and subjected to a warmed, humidified mixture of 8% oxygen/92% nitrogen bubbled through 37°C water and delivered at 4 l/min for 140 min. After this hypoxic exposure, the pups were returned to their dams and allowed to recover and grow for the following experiments. Pups were euthanized and brains were collected at different time points for brain VEGF levels, brain water content, Akt and ERKs assay and were then studied 3 and 22 d after HI for brain injury measurement.
Drug treatment. Pups from each litter were randomly assigned, marked and treated with VEGF (human recombinant VEGF 165 , Sigma Chemical Co.-Aldrich Co., St. Louis, MO) or vehicle according to the method described by Cheng et al. (19) with minor modification. VEGF 5, 10, 20, or 40 ng in 2 l phosphate-buffered saline (PBS) was administered intracerebroventricularly (i.c.v.) 5 min after reoxygenation following HI (n ϭ 19 -33 in each, see Table 1 ). These doses were chosen from a previous study (11) . The corresponding vehicle-treated pups were given the same volume of PBS (n ϭ 19 -29 in each, see Table 1 ). The location of each injection in relation to lambda was 2.0-mm rostral, 1.5-mm lateral, and 2.0-mm deep to the skull surface. The sham-operated pups (n ϭ 20) were treated similarly to the operated ones, except that the carotid artery was not ligated and they were not exposed to hypoxia.
Measurement of rectal temperature and body weight. To evaluate whether neuroprotection by VEGF was dependent on systemic hypothermia, rectal temperature was measured with a 36-gauge flexible thermocouple (Omega Engineering Inc., Stamford, CT). This was done in 12 pups from 1 litter (six from the vehicle group and six given 10 ng of VEGF) before hypoxia; and at 0 and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, and 4 h after reoxygenation following HI.
Body weight was measured in the rat pups (vehicle, n ϭ 88; VEGF 5 ng, n ϭ 19, 10 ng, n ϭ 19, 20 ng, n ϭ 33, or 40 ng, n ϭ 20) at 0, 1, 4, 7, 11, 14, and 22 d after injury.
Measurement of brain water content. To examine whether VEGFs beneficial effect might be offset by increased cerebral edema, brain water content was measured. Using the above neonatal HI procedure, the rat pups were treated with vehicle or VEGF. At 24 h after HI, the pups were decapitated, the brains rapidly removed and the hemispheres were divided. The samples were weighed and then dried at 95°C for 48 h to obtain the dry weight. The brain water content was calculated as [(wet weight Ϫ dry weight)/wet weight ϫ 100].
Measurement of brain levels of VEGF protein. Using the above neonatal HI procedure, the rat pups were treated with vehicle or 10 ng of VEGF. At 15, 45 min, 6, 24 h, 2 and 3 d (n ϭ 5-8 in each group) after administration, the pups were decapitated, the brains removed, the cortexes (right hemisphere) were dissected and frozen at Ϫ80°C. VEGF protein levels were determined using the Quantikine, mouse VEGF Immunoassay kit (R & D Systems, Minneapolis, MN) according to the manufacturer's instructions. This assay employs the quantitative sandwich enzyme immunoassay technique and recognizes all major isoforms of VEGF. The levels of VEGF protein in the brain were normalized and expressed as picograms per milligram of total brain protein.
Gross brain damage grading. Rat pups were decapitated 22 d after hypoxic exposure. The brains were scored normal, mild, moderate or severe by a blinded observer according to the method of Palmer et al. (20) . Normal (0) is no reduction in the size of the right hemisphere, mild (1) is visible reduction in right hemisphere size, moderate (2) is large reduction in hemisphere size from a visible infarct in the right parietal area, and severe (3) is near total destruction of the hemisphere. After removing the cerebellum and brainstem, the brain was divided into two hemispheres and weighed. Results are presented as the percent loss of hemispheric weight of the right side relative to the left [(left Ϫ right)/left ϫ 100]. This HI model results in brain damage only on the right side (4, 20) . There is a high degree of correspondence between the weight deficit of the injured hemisphere and histologically evaluated loss of brain tissue (21) . Microscopic brain damage grading. To verify that the gross changes were a reflection of the expected histopathologic changes, microscopic examination of the tissues after hematoxylin and eosin staining was carried out in 26 rat pups [13 in each group treated with VEGF (10 ng) or vehicle] 3 d after injury using the previously described method (21) . The cerebral cortex, thalamus, and hippocampus were scored by an observer blind to the treatment group of the animal on a range from 0 to 5 according to the method of Cataltepe et al. (22) where "0" is normal; "1" is 1-5% of neurons damaged; "2" is 6 -25% of neurons damaged; "3" is 26 -50% of neurons damaged; "4" is 51-75% of neurons damaged; and "5" is Ͼ75% of neurons damaged.
Western blot analysis for Akt and ERKs. To determine the effect of VEGF on Akt and ERKs proteins, Akt and ERKs proteins were measured in rat pups undergoing the above neonatal HI procedure, treated with vehicle or 10 ng of VEGF. At 45 min, 6 and 24 h (n ϭ 5-7 in each group) after reoxygenation following HI, the pups were decapitated, brains were removed, and cortexes in both right and left hemispheres were separately dissected and were frozen at Ϫ80°C. Akt and ERK proteins were assessed as described by Hasegawa et al. (23) . Samples with 30 g of protein were denatured and separated electrophoretically and transferred to a PVDF membrane. After incubation in 5% (W/V) nonfat-dried milk in Tris-Buffered saline (TBS) with 0.1% Tween 20, the membranes were washed and incubated at 4°C overnight with the primary antibodies. Anti-Akt (1:1000), antiphospho-Ser-473 Akt (1:200) and anti-p44/42 MAP kinase (1:500) antibodies were obtained from Cell Signaling Technology (Beverly, MA). Antiphospho ERK-1/2 (1:500) antibody was obtained from Sigma Chemical Co., Aldrich (St. Louis, MO). After washes, the membranes were incubated with 1:3000 diluted secondary antibodies of horseradish peroxidase-conjugated to antirabbit antibody (Amersham Life Science Inc., Heights, IL) or antimouse antibody (Transduction Laboratories, Lexington, KY) for 1 h at room temperature. The membranes were washed, then incubated in Amersham's Electrochemiluminescence (ECL TM ) Western blotting detection reagents and exposed to ECL Hyperfilm (Amersham, IL). Films were scanned using a Logitech Scanman densitometer (Logitech, Inc., Freemont, CA).
Statistical analysis. Categorical variables were analyzed with the 2 test. Ordinal variables were compared using Mann-Whitney rank sum test. Other variables were expressed as mean Ϯ SEM and the statistical significance of differences between groups was determined using the t test. Differences were considered significant at p Ͻ 0.05. The size of the groups was chosen to provide an 80% chance at the 0.05 level of detecting a reduction in percentage (%) loss of the right brain weight by 1/3 due to HI following i.c.v. VEGF treatment.
RESULTS
VEGF did not affect temperature, body weight, and mortality. Rectal temperatures were not significantly different between 10 ng of VEGF and vehicle treated pups at any time (group and group by time differences). Body weights of the VEGF treated groups were not significantly different from vehicle treated pups before injury or at 1, 4, 7, 11, 14, or 22 d after injury. Body weights increased significantly with time in all groups as the pups grew older. Mortality was not significantly different between VEGF (1 of 92 pups, 1.1%) and vehicle (3 of 91 pups, 3.3%, p ϭ 0.6) treated pups.
Brain water content. Brain water content was measured at 24 h after HI for rat pups treated with VEGF or vehicle. Brain water content was significantly increased in the right hemisphere in vehicle treated groups relative to the left hemisphere and sham group. Treatment with VEGF (40 ng, but not 5, 10, or 20 ng) reduced this increase compared with the vehicle (p Ͻ 0.05, Fig. 1) .
VEGF significantly increased the levels of brain VEGF at 15 min after injection. Brain VEGF levels were 312.7 Ϯ 6.2 pg/mg in sham pups. Brain VEGF levels were 555.6 Ϯ 65.4 and 370.2 Ϯ 40.8 pg/mg at 15 min after treatment with VEGF Fig. 2 ). At 45 min and 6 h after treatment, levels of brain VEGF rose 5-to 3-fold in both VEGF and vehicle groups, likely due to HI. Compared with sham, levels of brain VEGF were significantly higher in both VEGF and vehicle groups at 1 and 2 d as well as in VEGF group at 3 d after HI. VEGF (10 and 20 ng) reduced the decrease in right hemisphere weight. Left hemisphere weight was not affected by the HI, and was not significantly different for vehicle at any dose of VEGF treated pups. The percent reduction in right hemispheric weight caused by HI is shown in Figure 3 . VEGF significantly reduced the decrease in right hemisphere weight from Ϫ23.8 Ϯ 3.8% in the vehicle treated pups (n ϭ 26) to Ϫ11.5 Ϯ 3.0% in the pups treated with 10 ng of VEGF (n ϭ 25, p Ͻ 0.05) and from Ϫ20.7 Ϯ 3.2% in the vehicle treated pups (n ϭ 29) to Ϫ12.1 Ϯ 2.5% in the pups treated with 20 ng VEGF (n ϭ 33, p Ͻ 0.05). Treatment with 5 and 40 ng of VEGF did not affect the reduction in right hemisphere weight.
VEGF (10 and 20 ng) reduced gross brain injury. The proportion of pup brain scored as normal and damaged (mild, moderate, and severe) is shown in Table 1 (Fig. 4) .
VEGF increased phosphorylation of Akt-Ser-473 and ERK-1/2 at 45 min after reoxygenation following HI. Time course of total Akt, total ERK-1/2 and phosphorylation of Akt-Ser-473 and ERK-1/2 activities were measured in pups treated with 10 ng of VEGF or vehicle and sampled at 45 min, 6 and 24 h after reoxygenation following HI (Fig. 5) . The activities were expressed as a percentage (%) increase in OD of the right hemisphere relative to the left hemisphere. As shown in Figure 5A and B, the Akt-Ser-473 phosphorylation activity was 92.6 Ϯ 6.1% in the sham group (n ϭ 5) and 110.7 Ϯ 6.7% in the vehicle group (n ϭ 6) and 132.9 Ϯ 4.6% in the VEGF treated group (n ϭ 7) at 45 min after reoxygenation. Figure 5C and D show that the phosphorylation of ERK-1 (44 kD) and ERK-2 (42 kD) activities were 130.3 Ϯ 8.0% and 135.7 Ϯ 8.1% in the VEGF groups (n ϭ 12), and 104.8 Ϯ 5.8% and 108.3 Ϯ 7.3% in the vehicle group (n ϭ 10) at 45 min after reoxygenation, respectively. Thus, treatment with VEGF significantly increased Akt-Ser-473 and ERK-1/2 phosphorylation at 45 min after reoxygenation (p Ͻ 0.05 versus vehicle). Treatment with VEGF did not affect Akt-Ser-473 (Fig. 5B) and ERK-1/2 phosphorylation (Fig. 5D ) at 6 and 24 h after reoxygenation following HI as compared with corresponding vehicle treated groups (p Ͼ 0.05, n ϭ 6 -7 in each). Total Akt and total ERK-1/2 activity did not change between VEGF and vehicle treated groups at any time point (p Ͼ 0.05, data not shown).
DISCUSSION
The most important finding of the present study is that i.c.v. VEGF given 5 min after reoxygenation following HI reduces brain injury in a neonatal rat model of HI as measured by gross brain damage grading and reduction in right hemisphere weight at 22 d after injury. The histopathologic changes 3 d after injury are also consistent with a reduction in delayed brain injury. VEGF treatment also increases Akt and ERKs phosphorylation 45 min after reoxygenation, which may have played an important role in neuroprotection.
To our knowledge, this is the first study that shows a neuroprotective role of i.c.v. VEGF in neonatal HI. Many studies in adult animals have investigated the effects of exogenous administered VEGF on ischemic brain injury. In an adult rat, temporary middle cerebral artery occlusion (MCAO) model, i.c.v. infusion of VEGF decreased infarct volume and brain edema (9) . In an adult mouse MCAO model, a single i.c.v. injection of VEGF (8 ng) given 1 or 3 h after reperfusion protected the brain against ischemia (11) . Interestingly, VEGF has been ineffective or detrimental when administered via the systemic route (11, 24) because it causes an immune response and does not cross the blood-brain barrier (BBB) (25) . In addition, when given systemically, VEGF likely stimulates luminal receptors that trigger opening of tight junctions or activate matrix metalloproteinases with a resultant increase in BBB permeability and increased neuronal cell death (11, 26, 27) . When given i.c.v., VEGF may be having topical effects in the surrounding brain. A study by Storkebaum et al. (25) showed that after i.c.v. delivery VEGF not only diffused into and accumulated in the adjacent brain parenchyma but remained intact for at least 3 h. Our ELISA data also suggest that VEGF diffuses into the surrounding brain parenchyma after i.c.v. delivery. In summary, doses (10 and 20 ng), and route (i.c.v.) of VEGF injection in our study are consistent with other reports. It is possible that VEGF may not have achieved therapeutic level at the lower dose of 5 ng. VEGF (40 ng) reduced cerebral edema due to HI but failed to show late neuroprotection. Reasons for the insufficiency of the higher dose are not entirely clear and demonstrate the need for further investigation. In our model, VEGF was given 5 min after reoxygenation, which was relatively early compared with most other studies. Abumiya et al. (24) suggest that early VEGF administration after cerebral ischemia aggravates injury but in that study VEGF was given systemically. VEGF does have a wider therapeutic window, at least in an adult mouse MCAO model (11) . This may not be the case in the newborn rat as our ELISA data showed an increase in endogenous VEGF within 45 min of reoxygenation in the newborn. Still, it will be worthwhile to evaluate the therapeutic time window of VEGF in the neonatal HI model in further studies.
VEGF increases vascular permeability, which could result in brain edema and therefore worsen ischemic brain injury Figure 5 . VEGF increased phosphorylation of Akt-Ser-473 and ERK-1/2 at 45 min after reoxygenation following HI. Rat pups treated with 10 ng of VEGF (f) or vehicle (Ⅺ). Representative protein bands from Western blots, A: for phosphorylation of Akt-Ser-473 (P-Akt), total Akt (T-Akt) and ␤ -Actin, C: phosphorylation of ERK-1/2 (P-ERK-1/2), total ERK-1/2 (T-ERK-1/2) and ␤ -Actin, sampled at 45 min after reoxygenation. L, left hemisphere; R, right hemisphere. B and D show that treatment with VEGF significantly increased AktSer-473 and ERK-1/2 phosphorylation respectively, at 45 min after reoxygenation (*p Ͻ 0.05 vs. vehicle). Treatment with VEGF did not affect Akt-Ser-473 or ERK-1/2 phosphorylation at 6 and 24 h after reoxygenation following HI. n ϭ 5-7 rat pups for each group. (28) . In our study, we found that VEGF does not cause an increase in brain water content in the brain hemisphere affected by HI. This substantiates a similar finding in adult animals (9) . It is possible that when administered i.c.v. it may have a more direct effect on neurons and less effect on endothelial cells. However, the possibility of worsening brain edema after HI brain injury in newborn animals by multiple doses or longer duration of VEGF cannot be completely ruled out.
Survival effects of VEGF on endothelial cells involves activation of the VEGFR-2 receptor and modulation of the phosphatidylinositol 3Ј-kinase (PI3 K)/Akt signaly pathways (29) . Many in vitro and in vivo studies suggest involvement of this pathway in neuroprotection by VEGF (7, 17, 18) . Likely downstream targets for activated Akt include Bcl-2 associated death protein (BAD), caspase 9, members of the Forkhead family of transcription factor (FOXO), CREB and NF-B (13, 17, 18) . Kilic et al. (18) have shown that VEGF protects axotomized retinal ganglion cells by activating Akt as well as ERKs pathways. ERKs pathways have been implicated previously in neuroprotection by hypoxic preconditioning (16) as well as by other growth factors, such as brain derived neural growth factor (BDNF) and erythropoietin (16, 17) . In our model, we found that VEGF caused an early and transient increase in Akt and ERKs phosphorylation, which may mediate neuroprotection.
There are limitations to this study. We have not examined whether VEGF remains intact in brain after administration. In addition, the role of ERKs pathways in neuroprotection after HI is controversial. Our interpretation of increases in ERKs phosphorylation by VEGF as one of the mechanisms of neuroprotection against HI is speculative. Previous studies showed that cerebral ischemia increased VEGF expression. In our model, we found a much earlier (45 min after reoxygenation) increase in VEGF expression compared with other reports (6 h). There is thus a question as to whether exogenous VEGF is able to modify neuroprotection in the ischemic brain. Any change in the critical reperfusion period early after HI can have long lasting effects. We believe that our findings of increased VEGF within 15 min, early and transient changes in Akt and ERKs phosphorylation (45 min after reoxygenation) and evidence of later neuroprotection by i.c.v. VEGF treatment corroborates its role in neuroprotection. In addition, there may be a difference in the distribution of endogenously induced and exogenously administered VEGF.
In summary, in a newborn rat model of HI, i.c.v. administration of VEGF had neuroprotective effects possibly associated with activation of Akt and ERKs pathways. These findings show the need for further studies with VEGF to evaluate a therapeutic time window, effects of multiple doses/longer duration of treatment, functional outcome and confirmation of the mechanisms. A major limitation of VEGF treatment is the need for i.c.v. delivery or a similar route to ensure its direct effects on the brain. Strategies to up-regulate VEGF expression very early in response to HI may provide a better alternative.
